HC Wainwright Trims Oncternal Therapeutics (NASDAQ:ONCT) Target Price to $28.00

Oncternal Therapeutics (NASDAQ:ONCT) had its price objective trimmed by HC Wainwright from $30.00 to $28.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, StockNews.com raised Oncternal Therapeutics from a sell rating to a hold rating in a report on Friday, March 8th.

Oncternal Therapeutics Trading Down 6.4 %

Oncternal Therapeutics stock opened at $8.80 on Monday. Oncternal Therapeutics has a twelve month low of $5.57 and a twelve month high of $13.14. The stock’s fifty day simple moving average is $8.95 and its 200-day simple moving average is $8.09. The firm has a market capitalization of $23.67 million, a P/E ratio of -0.65 and a beta of 1.26.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($3.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.09) by ($0.02). Oncternal Therapeutics had a negative return on equity of 95.87% and a negative net margin of 5,029.17%. The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same period in the prior year, the company posted ($4.00) EPS. Sell-side analysts predict that Oncternal Therapeutics will post -12.03 earnings per share for the current year.

Insider Activity at Oncternal Therapeutics

In other Oncternal Therapeutics news, Director Robert James Wills bought 3,086 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average price of $8.96 per share, with a total value of $27,650.56. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $89,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired 10,714 shares of company stock valued at $92,736 over the last quarter. 8.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Oncternal Therapeutics

Large investors have recently bought and sold shares of the stock. Mirabella Financial Services LLP acquired a new position in Oncternal Therapeutics in the first quarter valued at $38,000. Prudential Financial Inc. acquired a new position in Oncternal Therapeutics in the second quarter valued at $32,000. Virtu Financial LLC acquired a new position in Oncternal Therapeutics in the second quarter valued at $48,000. Citadel Advisors LLC acquired a new stake in shares of Oncternal Therapeutics during the fourth quarter worth about $29,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Oncternal Therapeutics during the first quarter worth about $99,000. Institutional investors and hedge funds own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.